9 - Tossicità Da Trattamento Radioterapico E Da Terapia Sistemica Per Neoplasia Vescicale.

transitional cell carcinoma of the bladder. J Urol 2002;167: 502-5. 21. Coloby PJ, Kakizoe T, Tobisu K and Sakamoto M. Urethral involvement in female bladder cancer patients: mapping of 47 consecutive cysto-urethrectomy specimens. J Urol 1994;152 (5 Pt 1):1438-42. 22. Chen ME, Pisters LL, Malpica A, Pettaway CA, Dinney CP. Risk of urethral, vaginal and cervical involvement in patients undergoing radical cystectomy for bladder cancer: results of a contemporary cystectomy series from M.D. Anderson Cancer Center. J Urol 1997;157:2120-3. 23. Baumann BC, Guzzo TJ, He J, et al. Bladder cancer patterns of pelvic failure: implications for adjuvant radiation therapy. Int J Radiation Oncol Biol Phys 2013; 85: 363-9. 24. Baumann BC, Bosch WR, Bahl A, et al. Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy Int J Radiat Oncol Biol Phys 2016; 96: 78-86. 25. Reddy AV, Christodouleas JP, Wu T, Smith ND, Steinberg GD, Liauw SL. External Validation and Optimization of International Consensus Clinical Target Volumes for Adjuvant Radiation Therapy in Bladder Cancer. Int J Radiat Oncol Biol Phys 2017; 97: 740-6. 26. Christodouleas JP, Hwang WT, Baumann BC. Adjuvant Radiation for Locally Advanced Bladder Cancer? A Question Worth Asking. Int J Radiat Oncol Biol Phys 2016; 94:1040-2. 27. Duchesne GM, Bolger JJ, Griffiths GO, et al. A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. Int J Radiat Oncol Biol Phys 2000; 47(2): 379-88. 28. Dirix P, Vingerhoedt S, Joniau S, Van Cleynenbreugel B, Haustermans K. Hypofractionated palliative radiotherapy for bladder cancer. Support Care Cancer 2016; 24: 181-6. 29. Mc Bain CA and Logue JP. Radiation therapy for muscle-invasive bladder cancer: treatment planning and delivery in the 21st century. Semin Radiat Oncol 2005; 15: 42-8. 30. Mangar SA, Miller NR, Khoo VS, et al. Evaluating inter-fractional changes in volume and position during bladder radiotherapy and the effect of volume limitation as a method of reducing the internal margin of the planning target volume. Clin Oncol (R Coll Radiol) 2008; 20: 698-704. 31. Foroudi F, Wilson L, Bressel M, et al. A dosimetric comparison of 3D conformal vs intensity modulated vs volumetric arc radiation therapy for muscle invasive bladder cancer. Radiat Oncol 2012; 7:111. 32. Pos F, Remeijer P. Adaptive management of bladder cancer radiotherapy. Semin Radiat Oncol 2010; 20: 116-20. 33. Kibrom AZ, Knight KA. Adaptive radiation therapy for bladder cancer: a review of adaptive techniques used in clinical practice. J Med Radiat Sci 2015; 62: 277-85. 34. Lacarrière E, Smaali C, Benyoucef A, Pfister C, Grise P. The efficacy of hemostatic radiotherapy for bladder cancer-related hematuria in patients unfit for surgery. Int Braz J Urol 2013; 39: 808-16. 35. Kaufman DS, Winter KA, Shipley WU, et al. Phase I–II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twicedaily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 2009; 73(4):833-7. 36. Mak RH, Zietman AL, Heney NM, Kaufman DS, Shipley WU. Bladder preservation: optimizing radiotherapy and integrated treatment strategies. BJU Int 2008;102(9 Pt B): 1345-53. 37. Kaufman DS, Winter KA, Shipley WU, et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000;5(6):471-6. 38. James ND, Hussain SA, Hall E, et al. Results of a phase III randomized trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle-invasive bladder cancer (MIBC) (BC2001 CRUK/01/004). J Clin Oncol 2010; 28(Suppl 15). 39. Pos FJ, Hart G, Schneider C and Sminia P. Radical radiotherapy for invasive bladder cancer: What dose and fractionation schedule to choose? Int J Radiat Oncol Biol Phys 2006; 64: 1168-73. 40. Moonen L, vd Voet H, de Nijs R, Horenblas S, Hart AA and Bartelink H. Muscle-invasive bladder cancer treated with external beam radiation: influence of total dose, overall treatment time, and treatment interruption on local control. Int J Radiat Oncol Biol Phys 1998; 42: 525-30. 41. Näslund I, Nilsson B, Littbrand B. Hyperfractionated radiotherapy of bladder cancer. A ten-year follow-up of a randomized clinical trial. Acta Oncol 1994; 33: 397-402. 42. Edsmyr F, Andersson L, Esposti PL, Littbrand B, Nilsson B. Irradiation therapy with multiple small fractions per day in urinary bladder cancer. Radiother Oncol 1985; 4 (3) 197-203. 43. Horwich A, Dearnaley D, Huddart R, et al. A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. Radiother Oncol 2005; 75: 34-43. 44. Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 2010; 28(33):4912-8. 45. Kouloulias V, Tolia M, Kolliarakis N, Siatelis A, Kelekis N. Evaluation of acute toxicity and symptoms palliation in a hypofractionated weekly schedule of external radiotherapy for elderly patients with muscular invasive bladder cancer. Int Braz J Urol 2013; 39: 77-82.